Alaproclate Uses, Dosage, Side Effects and more
Alaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s. Development was discontinued due to concerns over hepatotoxicity observed in animal studies. Alaproclate has also been found to act as a non-competitive NMDA receptor antagonist although without discriminative stimulus properties similar to phencyclidine.
| Attribute | Details |
|---|---|
| Trade Name | Alaproclate |
| Generic | Alaproclate |
| Alaproclate Other Names | Alaproclate |
| Type | |
| Formula | C13H18ClNO2 |
| Weight | Average: 255.74 Monoisotopic: 255.1026065 |
| Groups | Experimental |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
